Aprogen Pharmaceuticals

About Aprogen Pharmaceuticals

Aprogen Inc. is a South Korean biopharmaceutical company focused on the development and manufacturing of antibody-based therapeutics. It was founded in March 2000 by a team that included three faculty members from the Korea Advanced Institute of Science and Technology (KAIST) and a principal investigator from the Korea Research Institute of Bioscience and Biotechnology (KRIBB). The company's President is Jaeseob Kim, who holds a Ph.D. in Microbiology from Seoul University.

The company operates as a contract development and manufacturing organization (CDMO), specializing in both novel biologic drugs and biosimilars. Its business model involves leveraging proprietary technologies for antibody and recombinant protein engineering to create a pipeline of biopharmaceutical products. Aprogen possesses end-to-end capabilities, from cell line and process development to pre-clinical and clinical trials. A key milestone was achieved in 2020 when it became the first Korean biopharmaceutical firm to be recognized as a unicorn, signifying a valuation over $1 billion. The company's growth has been marked by several mergers and acquisitions, including a 2022 merger between its affiliate, Aprogen Pharmaceuticals, and Aprogen Biologics, which led to a listing on the KOSPI.

Aprogen's product development focuses on biosimilars for blockbuster drugs like Herceptin, Humira, and Remicade, as well as novel biopharmaceuticals for conditions such as degenerative arthritis and various cancers. One of its lead biosimilar candidates, GS-071, has completed Phase 3 clinical trials in the U.S. and launched in Japan. The company's revenue is generated through the development, manufacturing, and out-licensing of these biopharmaceutical products. A significant partnership includes a long-term supply and licensing agreement with Japan's Nichi-Iko Pharmaceutical Co., Ltd. To support its manufacturing, Aprogen constructed the Osong cGMP Plant, which utilizes an efficient perfusion system for cell culturing, enhancing production capacity.